New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.
The nanoscale docetaxel particles use silicon dioxide aerogel as a carrier of the docetaxel.
A novel process is outlined for the synthesis or preparation of docetaxel with the help of novel alloy for the deprotection of the protected docetaxel and its conversion into docetaxel.
The present invention provides crystalline polymorphs of docetaxel and processes for preparing them, a method for preparing amorphous docetaxel, and a process for preparing docetaxel.
The rate of release of the Docetaxel from the Docetaxel polymer derivative so obtained is regulated by adjusting the proportion of bound Docetaxel on the block copolymer and/or the number of bonds.
The median time to progression was 186 days (docetaxel + capecitabine) versus 128 days (docetaxel alone).
Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).
The median time to progression was 186 days (docetaxel + capecitabine) vs. 128 days (docetaxel alone).
The median time to progression was 186 days (docetaxel + capecitabine) vs. 128 days (docetaxel alone).
Median survival was 442 days (capecitabine + docetaxel) vs. 352 days (docetaxel alone).
A composition for injection comprising docetaxel and polysorbate 80, wherein the mass ratio between docetaxel and polysorbate 80 is 1 : 26.75.
The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).
The median time to progression was 186 days (docetaxel + capecitabine) versus 128 days (docetaxel alone).
The median time to progression was 186 days (docetaxel + capecitabine) versus 128 days (docetaxel alone).
The present invention relates to a novel anhydrous crystalline form of docetaxel.
The median time to progression was 186 days (capecitabine + docetaxel) vs. 128 days (docetaxel alone).
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод